Cargando…

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Multiple system atrophy (MSA) is a rare, severe, and rapidly progressive neurodegenerative disorder categorized as an atypical parkinsonian syndrome. With a mean life expectancy of 6–9 years after diagnosis, MSA is clinically characterized by parkinsonism, cerebellar ataxia, autonomic failure, and p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mészáros, Lisa, Hoffmann, Alana, Wihan, Jeanette, Winkler, Jürgen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215736/ https://www.ncbi.nlm.nih.gov/pubmed/32316335 http://dx.doi.org/10.3390/ijms21082775

Ejemplares similares

Human alpha-synuclein overexpressing MBP29 mice mimic functional and structural hallmarks of the cerebellar subtype of multiple system atrophy
por: Mészáros, Lisa, et al.
Publicado: (2021)

Current experimental disease-modifying therapeutics for multiple system atrophy
por: Lemos, Miguel, et al.
Publicado: (2021)

Symptomatic Care in Multiple System Atrophy: State of the Art
por: Grossauer, Anna, et al.
Publicado: (2022)

Oligodendroglial α‐synucleinopathy‐driven neuroinflammation in multiple system atrophy
por: Hoffmann, Alana, et al.
Publicado: (2019)

Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?
por: Sidoroff, Victoria, et al.
Publicado: (2022)

Multiple system atrophy
por: Goh, Yee Yen, et al.
Publicado: (2023)

Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis
por: Dorst, Johannes, et al.
Publicado: (2017)

Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy
por: Palacios, Santiago, et al.
Publicado: (2016)

Brain Atrophy as an Outcome of Disease-Modifying Therapy for Remitting-Relapsing Multiple Sclerosis
por: Chylińska, Magdalena, et al.
Publicado: (2023)

Models of multiple system atrophy
por: Lee, He-Jin, et al.
Publicado: (2019)

Heterogeneity of Multiple System Atrophy: An Update
por: Jellinger, Kurt A.
Publicado: (2022)

The genetic basis of multiple system atrophy
por: Tseng, Fan Shuen, et al.
Publicado: (2023)

Cerebrospinal Fluid Metabolome in Parkinson’s Disease and Multiple System Atrophy
por: Kwon, Do Hyeon, et al.
Publicado: (2022)

Current treatment options for postmenopausal vaginal atrophy
por: Naumova, Iuliia, et al.
Publicado: (2018)

Bone Marrow-Derived Mesenchymal Stem Cell Therapy as a Candidate Disease-Modifying Strategy in Parkinson's Disease and Multiple System Atrophy
por: Lee, Phil Hyu, et al.
Publicado: (2009)

Animal models of multiple system atrophy
por: Stefanova, Nadia, et al.
Publicado: (2015)

Multiple System Atrophy: Genetic or Epigenetic?
por: Sturm, Edith, et al.
Publicado: (2014)

Tremor in Multiple System Atrophy – a review
por: Kaindlstorfer, Christine, et al.
Publicado: (2013)

Lipid dysfunction and pathogenesis of multiple system atrophy
por: Bleasel, Jonathan M, et al.
Publicado: (2014)

An update on the cerebellar subtype of multiple system atrophy
por: Ciolli, Ludovico, et al.
Publicado: (2014)

Animal modeling an oligodendrogliopathy – multiple system atrophy
por: Bleasel, Jonathan M., et al.
Publicado: (2016)

Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy(1)
por: Jellinger, Kurt A.
Publicado: (2018)

Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment
por: Cortelli, Pietro, et al.
Publicado: (2019)

Current and emerging treatment options for spinal muscular atrophy
por: Farooq, Faraz, et al.
Publicado: (2015)

Prognostic Factors and Treatment‐Effect Modifiers in Spinal Muscular Atrophy
por: Baranello, Giovanni, et al.
Publicado: (2021)

Exploring Myelin Dysfunction in Multiple System Atrophy
por: Wong, Joanna H., et al.
Publicado: (2014)

Multiple System Atrophy: Advances in Diagnosis and Therapy
por: Watanabe, Hirohisa, et al.
Publicado: (2023)

Pareidolia in Parkinson's Disease and Multiple System Atrophy
por: Kurumada, Kentaro, et al.
Publicado: (2021)

Extracellular Interactions of Alpha-Synuclein in Multiple System Atrophy
por: Valdinocci, Dario, et al.
Publicado: (2018)

Multiple system atrophy: clinicopathological characteristics in Japanese patients
por: OZAWA, Tetsutaro, et al.
Publicado: (2017)

Is Multiple System Atrophy a Prion-like Disorder?
por: Jellinger, Kurt A., et al.
Publicado: (2021)

Role of Oligodendrocyte Lineage Cells in Multiple System Atrophy
por: Hsiao, Jen-Hsiang T., et al.
Publicado: (2023)

Editorial: Targeting α-Synuclein in Parkinson's Disease and Multiple System Atrophy
por: Fellner, Lisa, et al.
Publicado: (2022)

Parkinson’s disease or multiple system atrophy: potential separation by quantitative susceptibility mapping
por: Marxreiter, Franz, et al.
Publicado: (2023)

Current Status of Treatment of Spinal and Bulbar Muscular Atrophy
por: Tanaka, Fumiaki, et al.
Publicado: (2012)

Non-Analgesic Symptomatic or Disease—Modifying Potential of TRPA1
por: Heber, Stefan, et al.
Publicado: (2019)

Diagnosing multiple system atrophy: current clinical guidance and emerging molecular biomarkers
por: Goolla, Meghana, et al.
Publicado: (2023)

Treatment of multiple system atrophy using intravenous immunoglobulin
por: Novak, Peter, et al.
Publicado: (2012)

Bereitschaftspotential in Multiple System Atrophy
por: Yang, Yi-Chien, et al.
Publicado: (2021)

Inflammation in multiple system atrophy
por: Leńska-Mieciek, Marta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_88nvm4jsch54a70gh1bqm3enb7